- Home
- ROIV vs LNTH Comparison
ROIV vs LNTH Comparison
Compare ROIV & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | LNTH |
|---|---|---|
| Founded | 2014 | 1956 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1B | 4.4B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | ROIV | LNTH |
|---|---|---|
| Price | $22.39 | $65.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | $24.31 | ★ $78.00 |
| AVG Volume (30 Days) | ★ 7.9M | 1.1M |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.39 |
| Revenue | $20,329,000.00 | ★ $1,525,933,000.00 |
| Revenue This Year | N/A | $0.01 |
| Revenue Next Year | $376.94 | $1.24 |
| P/E Ratio | ★ N/A | $27.10 |
| Revenue Growth | N/A | ★ 1.95 |
| 52 Week Low | $8.73 | $47.25 |
| 52 Week High | $23.47 | $111.29 |
Technical Indicators
Market Signals| Indicator | ROIV | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 61.61 | 67.34 |
| Support Level | $21.60 | $64.13 |
| Resistance Level | $23.47 | $67.01 |
| Average True Range (ATR) | 0.88 | 2.17 |
| MACD | 0.06 | 0.32 |
| Stochastic Oscillator | 69.09 | 84.68 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.